← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Cardiometabolic Risk in Diabetes: Blood Pressure, Cholesterol, and Heart Outcomes

Evidence related to blood pressure, lipid profile, cardiovascular risk, cardiovascular events, and cardiometabolic risk markers in diabetes.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/cardiometabolic-risk

Executive Summary

Cardiometabolic Risk evidence appears to center on Exercise therapy.

Among 21 indexed studies and 5 interventions, the strongest signals are summarized from the available evidence. Exercise therapy appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
21
Evidence relationships
25
Interventions
5
Outcomes
10
Strong evidence signals
1
Mixed evidence areas
3

Key Findings

  1. 01

    Across 3 studies, Exercise therapy shows a consistent strong positive signal for Systolic blood pressure.

  2. 02

    Across 2 studies, Exercise therapy shows a moderate positive signal for HDL cholesterol.

  3. 03

    Across 2 studies, Mediterranean diet shows a moderate positive signal for Triglycerides.

  4. 04

    Across 2 studies, Metformin shows a moderate positive signal for LDL cholesterol.

Question Highlights

Does Exercise therapy improve systolic blood pressure?

Exercise therapy appears to improve systolic blood pressure.

Strong evidence is based on 3 supporting studies.

Read the full answer

Does Metformin improve ldl cholesterol?

Metformin may improve ldl cholesterol.

Moderate evidence is based on 2 supporting studies.

Some evidence reported benefits while other evidence found little or no effect.

Read the full answer

Do SGLT2 inhibitors improve systolic blood pressure?

SGLT2 inhibitors may improve systolic blood pressure.

Moderate evidence is based on 2 supporting studies.

Some evidence reported benefits while other evidence found little or no effect.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Exercise therapy appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

Exercise therapy

Evidence basis: 6 evidence pairs - 5 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Exercise therapy is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Exercise therapy · Metformin · Resistance training

Evidence basis: 25 evidence pairs - 21 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Mediterranean diet may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Mediterranean diet · SGLT2 inhibitors

Evidence basis: 9 evidence pairs - 7 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—